(Q37367235)

20 August 2017

1 reference

title

Improving stem cell mobilization strategies: future directions (English)

1 reference

20 August 2017

W Bensinger

1

1 reference

20 August 2017

J F DiPersio

series ordinal

2

1 reference

20 August 2017

J M McCarty

series ordinal

3

1 reference

20 August 2017

language of work or name

English

0 references

publication date

12 January 2009

1 reference

Bone Marrow Transplantation

20 August 2017

1 reference

20 August 2017

43

1 reference

20 August 2017

3

1 reference

20 August 2017

181-195

1 reference

https://scigraph.springernature.com/pub.10.1038/bmt.2008.410

20 August 2017

0 references

cites work

Non-Hodgkin lymphoma: an update

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Serum M-spike and transplant outcome in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

What is the optimum number of CD34+ peripheral blood stem cells for an autologous transplant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Management strategies for the hard-to-mobilize patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Factors for PBPC collection efficiency and collection predictors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Selection and use of chemotherapy with hematopoietic growth factors for mobilization of peripheral blood progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Cytokines and hematopoietic stem cell mobilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: risk factors, cytokine use and cost.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Mechanisms of hematopoietic stem cell mobilization: when innate immunity assails the cells that make blood and bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Peripheral blood stem cell mobilization: the CXCR2 ligand GRObeta rapidly mobilizes hematopoietic stem cells with enhanced engraftment properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Comparison between granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the mobilization of peripheral blood stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

CD34+ cell adhesion molecule profiles differ between patients mobilized with granulocyte-colony-stimulating factor alone and chemotherapy followed by granulocyte-colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Mobilization of peripheral blood progenitor cells with vinorelbine and granulocyte colony-stimulating factor in multiple myeloma patients is reliable and cost effective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Soluble c-kit receptor mobilizes hematopoietic stem cells to peripheral blood in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Synergistic mobilization of hemopoietic progenitor cells using concurrent beta1 and beta2 integrin blockade or beta2-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Impact of stem cell dose on hematopoietic recovery in autologous blood stem cell recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Mobilization of hematopoietic stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Differential mobilization of CD34+ cells and lymphoma cells in non-Hodgkin's lymphoma patients mobilized with different growth factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Characterization of hematopoietic progenitor mobilization in protease-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Neutrophils are indispensable for hematopoietic stem cell mobilization induced by interleukin-8 in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Engraftment syndrome in children undergoing autologous peripheral blood progenitor cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m2) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Simultaneous administration of G-CSF and GM-CSF for re-mobilization in patients with inadequate initial progenitor cell collections for autologous transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Lineage-specific hematopoietic growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Erythropoietin in stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Successful mobilization of peripheral blood stem cells using recombinant human stem cell factor in heavily pretreated patients who have failed a previous attempt with a granulocyte colony-stimulating factor-based regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Quantification of the peripheral blood colony forming unit-culture rise following chemotherapy. Could leukocytaphereses replace bone marrow for autologous transplantation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

The phenotypic profile of CD34-positive peripheral blood stem cells in different mobilization regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(-2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Single versus double autologous stem-cell transplantation for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: efficacy and toxicity at three dose levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

ATP-dependent activation of the intermediate conductance, Ca2+-activated K+ channel, hIK1, is conferred by a C-terminal domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Thrombocytopenia caused by the development of antibodies to thrombopoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

The impact of thrombopoietin on clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Relation between harvest success and outcome after autologous peripheral blood stem cell transplantation in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

Role of bone marrow transplantation in the disease pathway of myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Cure of multiple myeloma -- more hype, less reality.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Bone Marrow Transplantation: Prognostic Factors of Peripheral Blood Stem Cell Mobilization with Cyclophosphamide and Filgrastim (r-metHuG-CSF): The CD34+ Cell Dose Positively Affects the Time to Hematopoietic Recovery and Supportive Requirements afte

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Predictive factors for long-term engraftment of autologous blood stem cells

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Characterization and outcome of "hard to mobilize"' lymphoma patients undergoing autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobilizers

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Factors that influence collection and engraftment of autologous peripheral-blood stem cells

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Hemopoietic progenitor cell mobilization and harvest following an intensive chemotherapy debulking in indolent lymphoma patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Rapid mobilization of murine hematopoietic stem cells with enhanced engraftment properties and evaluation of hematopoietic progenitor cell mobilization in rhesus monkeys by a single injection of SB-251353, a specific truncated form of the human CXC

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Cyclophosphamide Mobilization Does Not Improve Outcome in Patients Receiving Stem Cell Transplantation for Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Cell-surface antigen expression in early and term gestation fetal hematopoietic progenitor cells

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Reversibility of CD34 expression on human hematopoietic stem cells that retain the capacity for secondary reconstitution

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Patients mobilizing large numbers of CD34+ cells ('super mobilizers') have improved survival in autologous stem cell transplantation for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's Lymphoma?

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Stem cell mobilization.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Neutrophil-derived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and the chemokines GRObeta/CXCL2 and GRObetaT/CXCL2delta4

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Successful PBSC mobilization with high-dose G-CSF for patients failing a first round of mobilization

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Factors influencing G-CSF-mediated mobilization of hematopoietic progenitor cells during steady-state hematopoiesis in patients with malignant lymphoma and multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Effects of high-dose granulocyte colony-stimulating factor on neutrophil functions

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Cytokines alone for PBPC collection in patients with advanced gynaecological malignancies: G-CSF vs G-CSF plus EPO

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Peripheral Blood Stem Cell Mobilization by Chemotherapy With and Without Recombinant Human Granulocyte Colony-Stimulating Factor

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Optimization of peripheral blood stem cell mobilization

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Stem cell mobilisation in lymphoproliferative diseases

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Therapeutic targeting of a stem cell niche

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Phase I trial of parathyroid hormone to facilitate stem cell mobilization

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.410

7 January 2021

Identifiers

DOI

10.1038/BMT.2008.410

1 reference

20 August 2017

1 reference